Bioptigen Receives FDA Clearance And Two Phase II SBIR Awards; Company To Exhibit At Major Technology Conference

Published: Jan 19, 2007

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Bioptigen, Inc., a Duke University Biomedical Engineering Department spin-out, has received FDA clearance to market its first generation spectral domain optical coherence tomography (SDOCT) imaging systems for imaging ocular tissue microstructure. Bioptigen systems offer non-invasive three-dimensional imaging of the retina and anterior surfaces of the eye fifty times faster than previous generation technologies, with axial resolution below six micrometers. Bioptigen systems are aimed at supporting advanced research in eye disease including glaucoma, macular degeneration, and diabetic retinopathy. Unique among competitive options, Bioptigen offers multiple scanning interfaces to support in-vivo imaging in humans and animals, as well as ex-vivo imaging of tissues. Bioptigen InVivoVueâ„¢ software provides superior image processing and maximum flexibility for the researcher.

Back to news